Lupin is one of India’s leading pharmaceutical companies, known for its strong presence in the global market. Investors are keen to know how its share price will perform in the coming years. With new drug launches, expanding markets, and growing demand for healthcare products, Lupin has the potential for steady growth. Lupin Share Price on 3 April 2025 is 2,092.55 INR. This article will provide more details on Lupin Share Price Target 2025, 2026 to 2030.
Lupin Company Info
- CEO: Vinita D. Gupta (Sept 2013–)
- Founder: Desh Bandhu Gupta
- Headquarters: Mumbai
- Number of employees: 19,210 (2024)
- Revenue: 16,715 crores INR (US$2.1 billion, 2023)
- Subsidiaries: Polynova Industries Limited.
Lupin Share Price Chart
Lupin Share Price Details
- Today Open: 2,100.00
- Today High: 2,150.00
- Today Low: 2,070.05
- Mkt cap: 95.24KCr
- P/E ratio: 33.37
- Div yield: 0.38%
- 52-wk high: 2,402.90
- 52-wk low: 1,493.30
Lupin Shareholding Pattern
- Promoters: 46.95%
- Foreign Institutions: 22.04%
- Mutual Funds: 16.92%
- Retails and others: 6.27%
- Domestic Institutions: 7.81%
Lupin Share Price Target Tomorrow 2025, 2026 To 2030
- 2025 – ₹2405
- 2026 – ₹3000
- 2027 – ₹4500
- 2028 – ₹6000
- 2029 – ₹7500
- 2030 – ₹8000
Lupin Share Price Target 2025
Lupin share price target 2025 Expected target could be ₹2405. As of April 2025, Lupin Limited has demonstrated notable performance in the pharmaceutical sector. Several key factors could influence its share price target for 2025:
-
Financial Performance: In Q3 FY2025, Lupin reported a 10.6% year-on-year increase in sales, reaching ₹5,619 crores, and achieved an EBITDA margin of 24.3%, the highest in five years. Consistent revenue growth and improved profitability are crucial for enhancing investor confidence and positively impacting the share price.
-
Market Expansion and Product Pipeline: Lupin’s strategic focus on expanding its product range and geographic reach has resulted in a portfolio exceeding 1,000 products available in over 100 countries. Successful launches in the U.S. market and a robust pipeline of generic and specialty drugs are expected to drive future growth.
-
Analyst Ratings and Target Prices: Brokerage firms have revised their outlook on Lupin. Goldman Sachs maintains a “Neutral” rating with a target price of ₹2,225, indicating a potential upside of nearly 10%. Axis Securities has an “Overweight” call with a target price of ₹2,500. These ratings reflect market sentiment and can influence investor decisions.
-
Regulatory Environment and Pricing Pressures: Inclusion of key products, such as the Albuterol inhaler, on lists subject to price caps can impact revenue streams. Navigating regulatory challenges and maintaining compliance are essential for sustaining growth and protecting market share.
-
Operational Efficiency and Cost Management: Achieving higher EBITDA margins, as seen in recent quarters, indicates effective cost management and operational efficiency. Continued focus on optimizing production costs and streamlining operations will be vital for maintaining profitability and supporting share price appreciation.
Lupin Share Price Target 2030
Lupin share price target 2030 Expected target could be ₹8000. Here are five key factors that could influence the Lupin share price target for 2030:
-
Global Market Expansion & New Product Launches – Lupin’s ability to expand into emerging markets and introduce innovative drugs, biosimilars, and specialty medications will be crucial for long-term revenue growth.
-
Research & Development (R&D) Investments – Increased investment in R&D for high-margin specialty drugs and complex generics can enhance profitability and boost investor confidence over the decade.
-
Regulatory Approvals & Compliance – The company’s ability to secure timely approvals from regulatory bodies like the USFDA, EMA, and CDSCO for new drugs and maintain quality standards will impact its market presence and stock valuation.
-
Mergers, Acquisitions & Strategic Partnerships – Collaborations with biotech firms, acquisitions of high-growth pharmaceutical assets, and strategic alliances can accelerate Lupin’s expansion and strengthen its competitive edge.
-
Macroeconomic & Healthcare Trends – Factors like rising healthcare demand, increasing generic drug adoption, government policies on pricing, and inflation will influence Lupin’s financial performance and share price trajectory.
Financial Statement Of Lupin
| (INR) | 2024 | Y/Y change |
| Revenue | 200.11B | 20.25% |
| Operating expense | 101.23B | 18.30% |
| Net income | 19.14B | 345.15% |
| Net profit margin | 9.57 | 270.93% |
| Earnings per share | 41.87 | 344.95% |
| EBITDA | 36.27B | 130.53% |
| Effective tax rate | 20.09% | — |
Read Also:- Manba Finance Share Price Target Tomorrow 2025, 2026 To 2030